EUCTR2015-004507-23-FI进行中（未招募）1 期
Efficacy and safety of ODM-104 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson’s disease and end-of-dose wearing-off. - COMPOC
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent (IC) obtained.
- •- Male or female patients with idiopathic PD according to the UK brain bank criteria with end-of-dose wearingoff (motor fluctuations).
- •- Hoehn and Yahr stage 2-4 performed during the ON-state.
- •- At least 2 hours of OFF-time on each day (measured by the ON/OFF diary) on 3 consecutive days at the end
- •of the screening period just before the baseline visit (visit 1).
- •- Treatment with 4-8 daily doses of levodopa/AADC inhibitor, either combined with entacapone
- •(levodopa/AADC inhibitor combined with Comtess/Comtan or as Stalevo) or without entacapone, with a total daily levodopa dose from > 400 mg to = 1200 mg with entacapone, or from > 400 mg to = 1400 mg without entacapone. One evening dose of controlled release formulation, 1 morning dose of soluble levodopa/AADC inhibitor, or both, as needed are allowed.
- •- Unchanged levodopa/AADC inhibitor with or without entacapone, and other antiparkinsonian medication
- •(dopamine agonists, monoamine oxidase [MAO] B inhibitor, amantadine and/or anticholinergics with doses
- •recommended by the manufacturer), if any, for at least 4 weeks before the screening visit.
- •- Age of 30 years or above.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •- Secondary or atypical Parkinsonism.
- •- Current use of tolcapone or opicapone (within 4 weeks before the screening visit).
- •- Previous tolerability problems with entacapone, tolcapone and opicapone.
- •- Concomitant treatment with apomorphine, MAO-A inhibitors or non-selective MAO inhibitors (within 4
- •weeks before the screening visit).
- •- Concomitant treatment with drugs having antidopaminergic action including alpha-methyldopa, reserpine and antipsychotic drugs (also D2 receptor blocking antiemetics except domperidone). As an exception to prohibit use of antipsychotic drugs, 1 evening dose of an atypical antipsychotic is allowed.
- •- Use of concomitant medicine which is predominantly metabolised by CYP3A4 and which has a narrow
- •therapeutic window such as ergot alkaloids, carbamazepine, cyclosporin, macrolides (sirolimus and
- •tacrolimus), quinidine or fentanyl.
- •- Current use of warfarin (within 4 weeks before the screening visit).
- •- Inability to refrain from use of any iron preparations during the study.
- •- Disabling dyskinesias.
- •- Problematic hallucinations within 3 months before the screening visit.
- •- Symptomatic orthostatic hypotension.
- •- Current dementia (Mini Mental State Examination [MMSE] score < 26).
- •- Problematic impulse control disorders (ICDs), such as pathological gambling, hypersexuality or compulsive
- •shopping within 6 months before the screening visit.
- •- History of neuroleptic malignant syndrome (NMS), non-traumatic rhabdomyolysis, or both.
- •- Any neurosurgical intervention for the treatment of PD, including deep brain stimulation (DBS).
- •- Narrow-angle glaucoma or pheochromocytoma.
- •- Any active malignant cancer.
- •- Clinically significant cardiovascular (e.g. ischaemic heart disease, ventricular or supraventricular arrhythmias), pulmonary, GI (e.g. inflammatory bowel disease), hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator would interfere with the interpretation of the study results or constitute a health risk for the subject if he/she takes part into the study.
- •- Alanine aminotransferase or aspartate aminotransferase > 1.25 x upper limit of normal (ULN) at screening.
- •- Any other abnormal value of laboratory, vital signs or ECG (such as QTcF prolongation = 450 ms) that may
- •in the opinion of the investigator interfere with the interpretation of the study results or cause health risk for
- •the subject if he/she takes part into the study.
- •- Female patients of childbearing potential (i.e. menstruating or less than 2 years postmenopausal).
- •- Patients with pre-planned surgery requiring hospitalisation during the study.
- •- Known hypersensitivity to active substances or to any of the excipients of the study treatments.
- •- Blood donation or loss of significant amount of blood within 60 days before screening visit.
- •- Participation in a drug study within 60 days before the first treatment period.
- •- Any other condition that in the opinion of the investigator would interfere with the interpretation of the study results or constitute a health risk for the subject if he/she takes part into the study.
- •- Failure to demonstrate acceptable/appropriate use of the ON/OFF diary despite adequate training during the
- •screening visit
研究者
相似试验
进行中（未招募）
1 期
Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.Parkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations)EUCTR2015-004507-23-HUOrion Corporation80
进行中（未招募）
1 期
Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.Parkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations)EUCTR2015-004507-23-DEOrion Corporation80
进行中（未招募）
1 期
Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.Parkinson's disease (PD) patients with end-of-dose wearing-off (motor fluctuations)EUCTR2015-004507-23-LVOrion Corporation60
进行中（未招募）
不适用
Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®) in patients with Parkinson’s disease.Parkinson's diseaseMedDRA version: 14.1Level: LLTClassification code 10013113Term: Disease Parkinson'sSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-022200-46-FIOrion Corporation100
进行中（未招募）
不适用
Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®) in patients with Pakinson’s disease.Parkinson's diseaseEUCTR2010-022200-46-DEOrion Corporation100